|
|
|
|
|
|
|
|
|
02.06.26 - 01:06
|
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting (Business Wire)
|
|
|
ONO-4578, an EP4 antagonist, in combination with OPDIVO® and chemotherapy demonstrated a statistically significant improvement in the primary endpoint of progression-free survival (PFS) compared to the placebo combination group (median PFS, 9.0 months vs. 6.9 months, respectively).
In the subgroup population with PD-L1 CPS ≥1, median PFS in the ONO-4578 combination group was 9.9 months, showing a marked clinical benefit compared to 5.7 months in the placebo combination group.
Based on these promising results, preparations are underway to initiate a phase 3 clinical study.
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced the results of the phase 2 clinical study (ONO-4578-08 study) of the EP4 antagonist ONO-4578 in patients with previously untreated, HER2-negative unresectable advanced or recurrent gastric cancer (including gastroesophageal junction cancer). The results were presented at the American Soc...
|
|
|
|
|
01.06.26 - 08:33
|
3D Investment Releases White Paper Presentation, Manga (Comic), and Dedicated Website to Call On Shareholders to Vote “AGAINST” Toho HD′s Proposed Poison Pill Invocation at the June AGM (Business Wire)
|
|
|
The Poison Pill defends against no legitimate threat; 3D's acquisition of additional shares is not aimed at seizing management control, nor does it impair corporate value or the common interests of shareholders.
The Board lacks the sufficient independence required to prevent management from abusing the Poison Pill for self-protection. Notably, this Pill was introduced just two months after 3D surfaced suspected, repeated misconduct (bid-rigging) by incumbent executives.
The Poison Pill endorses that entrenchment and weakens managerial discipline, locking shareholders into recent underperformance and a flawed new mid-term plan.TOKYO--(BUSINESS WIRE)--A fund to which 3D Investment Partners Pte. Ltd. (together with the funds, “3D” or “we”) provides discretionary investment management services has held shares of Toho Holdings Co., Ltd. (TOKYO: 8129, “Toho HD”) continuously since it began investing in July 2020 and 3D currently holds approximately 24% of the voting rights.
Today, 3D published a co...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.05.26 - 08:01
|
Enhertu recommended in EU for HER2+ solid tumours (Cision)
|
|
|
26 May 2026
Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours
Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showed clinically meaningful responses across a broad range of tumours
If approved, Enhertu would become the first HER2-directed therapy and
antibody drug conjugate to receive a tumour agnostic indication in the EU
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a...
|
|
|
26.05.26 - 08:01
|
Datroway approved in US for 1L triple-negative BC (Cision)
|
|
|
26 May 2026
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo's Datroway is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with an unprecedented median overall survival of approximately two years based on the TROPION-Breast02 Phase III trial
Datroway has the potential to become the new standard of care in this setting...
|
|
|
|
|
25.05.26 - 12:30
|
Eisai Expects Revenue Of JPY 1 Trillion For 2028 (AFX)
|
|
|
TOKYO (dpa-AFX) - Eisai Co., Limited (ESALY.PK, ESALF.PK, 4523.T, EII.SG), a Japanese pharmaceutical company, said on Monday that it expects revenue of JPY 1 trillion for fiscal 2028, helped by th......
|
|
|
25.05.26 - 12:00
|
AstraZeneca, Daiichi Sankyo′s Datroway receives FDA approval for TNBC (PBR)
|
|
|
The approval allows Datroway to be used as a first-line treatment for adults with unresectable or metastatic TNBC who cannot receive programmed cell death protein 1 (PD-1) or
The post AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC appeared first on Pharmaceutical Business review....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
